Screener
Beam Therapeutics BEAM Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:22 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210338
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Proceeds from issuances of stock under ESPP | 1,510 | 1,501 |
| Proceeds from exercise of stock options | 2,025 | 719 |
| Proceeds from the issuance of debt, net of fees paid to lender | 93,886 | — |
| Payments of debt issuance costs | (813) | — |
| Net cash provided by (used in) financing activities | 96,608 | 473,379 |
| Net change in cash, cash equivalents and restricted cash | (6,636) | 244,406 |
| Cash, cash equivalents and restricted cash—beginning of period | 301,620 | 290,111 |
| Cash, cash equivalents and restricted cash—end of period | $294,984 | $534,517 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Beam Therapeutics's net change in cash?
- Beam Therapeutics (BEAM) reported net change in cash of -$6.64M in Q1 2026.
- How has Beam Therapeutics's net change in cash changed year-over-year?
- Beam Therapeutics's net change in cash decreased by 102.7% year-over-year, from $244.41M to -$6.64M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Beam Therapeutics's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude